Cargando…

Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

[Image: see text] Many initially successful anticancer therapies lose effectiveness over time, and eventually, cancer cells acquire resistance to the therapy. Acquired resistance remains a major obstacle to improving remission rates and achieving prolonged disease-free survival. Consequently, novel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mumenthaler, Shannon M., Foo, Jasmine, Leder, Kevin, Choi, Nathan C., Agus, David B., Pao, William, Mallick, Parag, Michor, Franziska
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2011
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3230244/ https://www.ncbi.nlm.nih.gov/pubmed/21995722 http://dx.doi.org/10.1021/mp200270v

Ejemplares similares

The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells
por: Mumenthaler, Shannon M, et al.
Publicado: (2015)

Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors
por: Foo, Jasmine, et al.
Publicado: (2013)

An Evolutionary Approach for Identifying Driver Mutations in Colorectal Cancer
por: Foo, Jasmine, et al.
Publicado: (2015)

Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia
por: Leder, Kevin, et al.
Publicado: (2011)

A high-content image-based method for quantitatively studying context-dependent cell population dynamics
por: Garvey, Colleen M., et al.
Publicado: (2016)

Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies
por: Foo, Jasmine, et al.
Publicado: (2009)

Correction: Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies
por: Foo, Jasmine, et al.
Publicado: (2009)

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance
por: de Klerk, Daniel J., et al.
Publicado: (2018)

Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors
por: Benes, Cyril H
Publicado: (2015)

Single cell dynamic phenotyping
por: Patsch, Katherin, et al.
Publicado: (2016)

A Method for Overcoming Plasma Protein Inhibition of Tyrosine Kinase Inhibitors
por: Young, David J., et al.
Publicado: (2021)

Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras
por: Song, Xiaoling, et al.
Publicado: (2021)

Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
por: Chang, Yoon Soo, et al.
Publicado: (2016)

mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer
por: Chiang, Chun-Te, et al.
Publicado: (2018)

A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer
por: Shaurova, Tatiana, et al.
Publicado: (2023)

Evolutionary Dynamics of Intratumor Heterogeneity
por: Iwasa, Yoh, et al.
Publicado: (2011)

Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance
por: Jia, Peilin, et al.
Publicado: (2013)

New Therapeutic Strategy for Overcoming Multidrug Resistance in Cancer Cells with Pyrazolo[3,4-d]pyrimidine Tyrosine Kinase Inhibitors
por: Podolski-Renić, Ana, et al.
Publicado: (2021)

Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors
por: Lindsay, Danika, et al.
Publicado: (2016)

The Therapeutic Implications of Plasticity of the Cancer Stem Cell Phenotype
por: Leder, Kevin, et al.
Publicado: (2010)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
por: Lai, Wei-Yun, et al.
Publicado: (2014)

Differential Evolutionary Wiring of the Tyrosine Kinase Btk
por: Nawaz, Hossain M., et al.
Publicado: (2012)

Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration
por: Krchniakova, Maria, et al.
Publicado: (2020)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

PB1771: OVERCOMING RESISTANCE TO TYROSINE KINASE INHIBITORS IN MYELOID LEUKEMIA CELLS THROUGH ENHANCED FERROPTOSIS
por: Chien, Chih-Fang Chang, et al.
Publicado: (2023)

Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients
por: Liu, Lin L., et al.
Publicado: (2015)

Eradication of Chronic Myeloid Leukemia Stem Cells: A Novel Mathematical Model Predicts No Therapeutic Benefit of Adding G-CSF to Imatinib
por: Foo, Jasmine, et al.
Publicado: (2009)

Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia
por: Katayama, Kazuhiro, et al.
Publicado: (2018)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells
por: Zhao, Xin-min, et al.
Publicado: (2016)

The role of histone lysine demethylases in cancer cells’ resistance to tyrosine kinase inhibitors
por: White, Jasmine Cassar, et al.
Publicado: (2019)

Overcoming Tyrosine Kinase Inhibitor Resistance in Transformed Cell Harboring SEPT9-ABL1 Chimeric Fusion Protein
por: Kawai, Hidetsugu, et al.
Publicado: (2019)

Bruton’s Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Dong, Xing-Duo, et al.
Publicado: (2020)

Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia
por: Jiang, Liling, et al.
Publicado: (2022)

Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis
por: Paech, Franziska, et al.
Publicado: (2017)

Latest progress in tyrosine kinase inhibitors
por: Pospelova, Tatiana V., et al.
Publicado: (2014)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pl8mga8pdfa91otr3sorptocd4